Lacripep for Corneal Wound Healing Study

Trial statusRecruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age21-55
SponsorHenry M. Jackson Foundation for the Advancement of Military Medicine

About this trial

The objective of this study is to evaluate the safety and effectiveness of Lacripep as a therapy for superficial corneal injury repair after Photorefractive keratectomy (PRK).

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Male or female, of any race, 21 years old and older

Active-duty U.S. military service members or their dependents eligible for care at Alexander T. Augusta Military Medical Center for 6-month period postoperatively

Desiring refractive correction of myopia up to -4.00 diopters (D) sphere with or without astigmatism 0 to -1.50 D and up to -4.00 D manifest spherical equivalent in both eyes

Stable refraction for the past year as demonstrated by a change in manifest refractive spherical equivalent of ≤ 0.50 diopters (D) in both eyes

Disqualifiers

Calculated ablation depth of greater than 75 microns or other conditions in either eye which in the judgement of the investigators will require use of prophylactic MMC

Signs of unstable or progressive myopia, keratoconus or keratoconus suspect in either eye

Abnormal corneal topographic findings in either eye e.g., keratoconus, pellucid marginal degeneration

Treatment targeted for monovision

Trial design

Design model

Single group

Treatments tested in this trial

  • 0.00025% Lacripep ophthalmic solution and Placebo

    Drug

    Participant will receive Lacripep in one eye and placebo in the other eye at the same time.

Treatment groups

88 Participants
are divided into 1 treatment group
Group A: TreatmentExperimental treatment 1 intervention

Trial outcomes

Primary outcomes

1

Efficacy of Lacripep

To determine the efficacy of Lacripep for corneal wound healing, epithelial thickness will be be measured using optical coherence tomography (OCT). OCT is a non-invasive imaging technique that uses light waves to create detailed images of tissue structures.

Time frame
Epithelial thickness assessment will be performed at 4 and 7 days postoperatively then at 1, 3 and 6 months postoperatively.

Secondary outcomes

1

Lacripep safety

To determine the safety of Lacripep, the return of corrected distance visual acuity (CDVA) will be measured using high contrast visual acuity test. Return of CDVA will be defined as percentage of eyes with no more than 1 CDVA line lost from preoperative baseline.

Time frame
From enrollment to the end of treatment at 6 months

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Henry M. Jackson Foundation for the Advancement of Military Medicine

Lead sponsor

TearSolutions, Inc.

Collaborator

Walter Reed National Military Medical Center

Collaborator